・Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol.
Hirano T, Kodera R, Hirashima T, Suzuki N, Aoki E, Hosoya M, Oshima T, Hayashi T, Koba S, Ohta M, Satoh N, Ito Y.
J Atheroscler Thromb. 2021 Apr 29. doi: 10.5551/jat.62789. Online ahead of print.

・Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients - A Randomized Controlled Trial.
Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H, Tsukamoto S, Hayashi T, Toshida T, Watanabe N, Hamazaki Y, Geshi E, Murakami M, Aihara K, Kaneko K, Yamada H, Kobayashi Y, Shinke T.
Circ J. 2020 Sep 25;84(10):1807-1817. doi: 10.1253/circj.CJ-20-0341. Epub 2020 Sep 12.

・Pancreatic fat accumulation evaluated by multidetector computed tomography in patients with type 2 diabetes.
Fukase A, Fukui T, Sasamori H, Hiromura M, Terasaki M, Mori Y, Hayashi T, Yamamoto T, Ohara M, Goto S, Nagaike H, Hirano T, Yamagishi SI.
J Diabetes Investig. 2020 Sep;11(5):1188-1196. doi: 10.1111/jdi.13243. Epub 2020 Apr 14.

・Relationship between glucose variability evaluated by continuous glucose monitoring and clinical factors, including glucagon-stimulated insulin secretion in patients with type 2 diabetes.
Ohara M, Hiromura M, Nagaike H, Kohata Y, Fujikawa T, Goto S, Sato N, Kushima H, Terasaki M, Yamamoto T, Mori Y, Hayashi T, Fukui T, Yamagishi SI, Hirano T.
Diabetes Res Clin Pract. 2019 Dec;158:107904. doi: 10.1016/j.diabres.2019.107904. Epub 2019 Oct 28.

・Association of glucose and blood pressure variability on oxidative stress in patients with type 2 diabetes mellitus and hypertension: a cross-sectional study.
Ohara M, Kohata Y, Nagaike H, Koshibu M, Gima H, Hiromura M, Yamamoto T, Mori Y, Hayashi T, Fukui T, Hirano T.
Diabetol Metab Syndr. 2019 Apr 11;11:29. doi: 10.1186/s13098-019-0425-y. eCollection 2019.

・Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population.
Yamamura S, Fukui T, Mori Y, Hayashi T, Yamamoto T, Ohara M, Fukase A, Sasamori H, Kobayashi T, Hirano T.
J Diabetes Investig. 2019 Nov;10(6):1480-1489. doi: 10.1111/jdi.13052. Epub 2019 Apr 19.

・Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.
Nagaike H, Ohara M, Kohata Y, Hiromura M, Tomoyasu M, Takada M, Yamamoto T, Hayashi T, Fukui T, Hirano T.
Diabetes Ther. 2019 Feb;10(1):215-228. doi: 10.1007/s13300-018-0560-8. Epub 2019 Jan 5.
PMID: 30612316 Free PMC article.

・Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
Yamamoto S, Hayashi T, Ohara M, Goto S, Sato J, Nagaike H, Fukase A, Sato N, Hiromura M, Tomoyasu M, Nakanishi N, Lee S, Osamura A, Yamamoto T, Fukui T, Hirano T.
Diabetes Res Clin Pract. 2018 Jun;140:339-346. doi: 10.1016/j.diabres.2018.03.032. Epub 2018 Mar 26.

・Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes.
Ohara M, Nagaike H, Goto S, Fukase A, Tanabe Y, Tomoyasu M, Yamamoto T, Hayashi T, Fukui T, Hirano T.
Diabetes Res Clin Pract. 2018 May;139:253-261. doi: 10.1016/j.diabres.2018.02.017. Epub 2018 Mar 1.

・Analysis of pancreatic volume in acute-onset, slowly-progressive and fulminant type 1 diabetes in a Japanese population.
Sasamori H, Fukui T, Hayashi T, Yamamoto T, Ohara M, Yamamoto S, Kobayashi T, Hirano T.
J Diabetes Investig. 2018 Sep;9(5):1091-1099. doi: 10.1111/jdi.12816. Epub 2018 Mar 13.

・Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels.
Hayashi T, Koba S, Ito Y, Hirano T.
Lipids Health Dis. 2017 Jan 26;16(1):21. doi: 10.1186/s12944-017-0417-6.

・Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T.
Cardiovasc Diabetol. 2017 Jan 13;16(1):8. doi: 10.1186/s12933-016-0491-5.
PMID: 28086872 Free PMC article. Clinical Trial.

・Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes.
Ohara M, Fukui T, Ouchi M, Watanabe K, Suzuki T, Yamamoto S, Yamamoto T, Hayashi T, Oba K, Hirano T.
Diabetes Res Clin Pract. 2016 Dec;122:62-70. doi: 10.1016/j.diabres.2016.09.025. Epub 2016 Oct 14.

・A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.
Yamamoto T, Fukui T, Higuchi A, Ohara M, Hayashi T, Hirano T.
Diabetol Int. 2016 Apr 13;7(4):425-431. doi: 10.1007/s13340-016-0269-8. eCollection 2016 Dec.

・Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
Ito R, Fukui T, Hayashi T, Osamura A, Ohara M, Hara N, Higuchi A, Yamamoto T, Hirano T.
Drugs R D. 2015 Sep;15(3):245-51. doi: 10.1007/s40268-015-0096-6.
PMID: 26224337 Free PMC article. Clinical Trial.

・Significant increase of apolipoprotein B48 levels by a standard test meal in type 2 diabetic patients with nephropathy.
Yamamoto T, Hirano T, Mori Y, Tokuno A, Nagashima M, Takada M, Morita R, Lee S, Hayashi T, Adachi M.
J Atheroscler Thromb. 2008 Aug;15(4):199-205. doi: 10.5551/jat.e558.

・The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Tokuno A, Hirano T, Hayashi T, Mori Y, Yamamoto T, Nagashima M, Shiraishi Y, Ito Y, Adachi M.
J Atheroscler Thromb. 2007 Jun;14(3):128-32. doi: 10.5551/jat.14.128.

・Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease.
Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, Adachi M.
Atherosclerosis. 2008 Mar;197(1):154-8. doi: 10.1016/j.atherosclerosis.2007.03.015. Epub 2007 Apr 25.

・Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease.
Hirano T, Hayashi T, Adachi M, Taira T, Hattori H.
Metabolism. 2007 Apr;56(4):462-3. doi: 10.1016/j.metabol.2006.11.002.

・Small dense LDL concentration is closely associated with serum apolipoprotein B, comparisons of non-LDL cholesterol or LDL cholesterol.
Hayashi T, Hirano T, Shiobara T, Suguro T, Adachi M.
Rinsho Byori. 2006 Jun;54(6):569-75.

・Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
Hayashi T, Hirano T, Yamamoto T, Ito Y, Adachi M.
Metabolism. 2006 Jul;55(7):879-84. doi: 10.1016/j.metabol.2006.02.014.